Medinol Adopts “Trojan Horse” Strategy To Beat Drug-Eluting Stents

Medinol will begin pilot clinical trials by the end of 2002 on an anti-restenosis drug delivery technology intended as an alternative to drug-eluting stents

More from Archive

More from Medtech Insight